Wells Fargo raises Cigna stock price target to $325 on valuation
Wells Fargo raised its price target for Cigna (CI) to $325 from $307, citing valuation, while lowering its 2027 and 2028 EPS estimates. Cigna's stock trades near its 52-week high. The company reported Q3 2026 earnings of $7.98 per share on $73.7B revenue, beating estimates. Analysts have mixed views on Cigna's future performance.
How this was made
The 30-second read
Why it matters
The upgrade may prompt short‑term buying, but mixed analyst sentiment and lower earnings forecasts temper the upside.
Market read
Analyst target raise provides a modest trading signal for CI, with limited broader market effect.
What to watch
Piper Sandler's lower target of $360 highlights divergent views on pharmacy benefit margins.
Background
Wells Fargo increased its price target for Cigna (CI) to $325 while cutting 2027‑2028 EPS estimates, citing reduced discounting despite lower earnings forecasts.
Ticker impact
Wells Fargo raised its price target for Cigna to $325, indicating a more favorable valuation despite lower earnings estimates.
likely upward pressure as the market prices in the higher target
Analyst price‑target upgrades often lead to short‑term buying interest, especially when the target exceeds current price.
Market effects
May lift sentiment in the health‑insurance sector as peers are re‑valued.
Limited to U.S. markets where Cigna trades.
Minimal global impact beyond U.S. health‑care investors.
Counterpoint
Target raise could be premature given lowered earnings forecasts and sector headwinds.
Key entities
- companyCigna
U.S. health services insurer (ticker CI).
- analystWells Fargo
Equity research firm raising CI price target.

